Altimmune, Inc. (ALT) News
Track canonical SquawkNews coverage tagged to ALT, Altimmune, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Alt Reports Wider Loss
Alt reports net loss of $22.8M, wider than $22.1M YoY
EARNINGS | Aug 12, 2026, 11:34 AM UTC
L
ALT Reports Q2 2026 Financial Results
Altimmune announces second quarter 2026 financial results and business update
EARNINGS | Aug 12, 2026, 11:30 AM UTC
L
ALT - Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
ALT - Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
EARNINGS | Aug 05, 2026, 12:01 PM UTC
M
Altimmune Initiates Pemvidutide Phase 3 Trial
Altimmune starts Phase 3 trial for Pemvidutide
EQUITY | Aug 03, 2026, 12:01 PM UTC
L
ALT gives up premarket gains of over 20% on drug headlines earlier; shares flat
ALT gives up premarket gains of over 20% on drug headlines earlier; shares flat
EQUITY | Jul 28, 2026, 02:18 PM UTC
L
ALT +18% premarket after trial headlines
ALT +18% premarket after trial headlines
EQUITY | Jul 28, 2026, 11:08 AM UTC
L
Watching Altimmune; Shares Move Higher, Traders Circulate Stock Picked By Popular Retail Traders Newsletter
Watching Altimmune; Shares Move Higher, Traders Circulate Stock Picked By Popular Retail Traders Newsletter
EQUITY | Jul 01, 2026, 02:57 PM UTC
M
ALT: Leerink Initiates
Leerink Partners initiates coverage on Altimmune with an Outperform rating and a price target of $10
EQUITY | Jun 22, 2026, 02:45 PM UTC
M
Banks Initiate Coverage
Multiple banks initiate coverage on various stocks with different ratings
EQUITY | Jun 22, 2026, 10:57 AM UTC